Avadel Pharmaceuticals Q3 EPS $(0.41) Vs $(0.33) Last Year, Sales $7.01M Beat $5.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals reported Q3 losses of $(0.41) per share, a 24.24% decrease from the same period last year. However, the company's quarterly sales of $7.01 million beat the analyst consensus estimate of $5.09 million by 37.80%.
November 08, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avadel Pharmaceuticals reported a larger loss than last year, but beat sales estimates.
While Avadel Pharmaceuticals reported a larger loss than last year, it beat sales estimates, which could have a mixed impact on the stock. Investors may be concerned about the increased loss, but encouraged by the higher than expected sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100